Simple Summary Studies conducted in a recent decade revealed that acute lymphoblastic
leukemia cells exploit various mechanisms to avoid immune recognition and destruction by …

Current intensified chemotherapy regimens have significantly increased survival rates for
pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL), but these treatments can …

Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are
refractory to immune checkpoint inhibitors (ICIs) 1, 2, partly because there are …

Protein kinase inhibitors are amongst the most successful cancer treatments, but targetable
kinases activated by genomic abnormalities are rare in T cell acute lymphoblastic leukemia …

B-cell acute lymphoblastic leukemia (B-ALL) occurs most commonly in children, whereas
chronic myeloid leukemia is more frequent in adults. The myeloid bias of hematopoiesis in …

Notch receptors deeply influence T-cell development and differentiation, and their
dysregulation represents a frequent causative event in “T-cell acute lymphoblastic …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of ALL characterized
by its high heterogeneity and unfavorable clinical features. Despite improved insights in …

Background The survival rate of children and adolescents with acute lymphoblastic
leukemia (ALL) has progressively improved. However, ALL survivors often have adverse …

The success of immunotherapy has highlighted the critical role of the immune
microenvironment in acute lymphoblastic leukemia (ALL); however, the immune landscape …

Kawasaki disease (KD) is an immune‐response disorder with unknown etiology. KD is an
acute systemic immune vasculitis caused by infectious factors that can be complicated by …